- Home
- TWO vs GLUE Comparison
TWO vs GLUE Comparison
Compare TWO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWO | GLUE |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TWO | GLUE |
|---|---|---|
| Price | $11.56 | $18.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $12.56 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.2M | 919.5K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 12.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $8.84 | $3.76 |
| 52 Week High | $14.17 | $25.77 |
Technical Indicators
Market Signals| Indicator | TWO | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 66.98 | 52.60 |
| Support Level | $9.74 | $17.36 |
| Resistance Level | $14.17 | $20.24 |
| Average True Range (ATR) | 0.10 | 1.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 93.70 | 33.02 |
Price Performance
Historical ComparisonAbout TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).